

Product datasheet for **TL312955V**

FMRP (FMR1) Human shRNA Lentiviral Particle (Locus ID 2332)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	FMRP (FMR1) Human shRNA Lentiviral Particle (Locus ID 2332)
Locus ID:	2332
Synonyms:	FMRP; FRAXA; POF; POF1; POFX
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	FMR1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001185075 , NM_001185076 , NM_001185081 , NM_001185082 , NM_002024 , NR_033699 , NR_033700 , NM_002024.2 , NM_002024.3 , NM_002024.4 , NM_002024.5 , NM_001185082.1 , NM_001185081.1 , NM_001185075.1 , NM_001185076.1 , BC086957 , BC038998 , NM_001185082.2 , NM_002024.6 , NM_001185081.2
UniProt ID:	Q06787
Summary:	The protein encoded by this gene binds RNA and is associated with polysomes. The encoded protein may be involved in mRNA trafficking from the nucleus to the cytoplasm. A trinucleotide repeat (CGG) in the 5' UTR is normally found at 6-53 copies, but an expansion to 55-230 repeats is the cause of fragile X syndrome. Expansion of the trinucleotide repeat may also cause one form of premature ovarian failure (POF1). Multiple alternatively spliced transcript variants that encode different protein isoforms and which are located in different cellular locations have been described for this gene. [provided by RefSeq, May 2010]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).